

Oncology Biosimilars Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, and Erythropoiesis-Stimulating Agents), Cancer Type (Colorectal Cancer, Cervical Cancer, Breast Cancer, Supportive Care, Lymphoma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

<https://marketpublishers.com/r/O02A23A33F1FEN.html>

Date: March 2024

Pages: 150

Price: US\$ 5,190.00 (Single User License)

ID: O02A23A33F1FEN

Abstracts

The oncology biosimilars market was valued at US\$ 9.46 billion in 2023 and is anticipated to reach US\$ 24.71 billion by 2031; it is projected to register a CAGR of 12.8% from 2023 to 2031.

Key factors driving the market growth are the surge in incidences of cancers, including lung cancer, colorectal cancer, and breast cancer; the cost-effectiveness of biosimilar drugs; and a rise in the approvals of oncology biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing hamper the oncology biosimilars market growth

Market Trends of the Oncology Biosimilars:

Collaboration models such as joint ventures can help biosimilar medicine manufacturers stay competitive. By collaborating with other companies, they can develop products quickly and effectively, access funding, and gain clinician and patient confidence. Collaboration can also provide access to established manufacturing facilities, and long-

term benefits include easy access to future production projects and early market penetration. A few instances of recent, high-profile collaborations in the oncology biosimilars market are given below:

In July 2023, Samsung Biologics and Pfizer signed a strategic partnership agreement for the long-term commercial manufacturing of Pfizer's multi-product portfolio. Under this agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilar portfolio covering oncology, inflammation, and immunology.

In March 2022, Cipla Medpro, along with the wholly-owned subsidiary of Cipla Limited in India, entered into a partnership agreement with mAbxience, the global biotechnology company, to provide oncology and respiratory-related biosimilars to South Africa. The partnership is aimed to ensure unbiased access to affordable, life-saving medication in the region.

Therefore, the collaborations among manufacturers for biosimilars and clinical trials are expected to bring new oncology biosimilars market trends in the coming years.

Oncology Biosimilars: Segmental Overview

The oncology biosimilars is segmented on the basis of drug class, cancer type, and distribution channel.

The market, by drug class, is segmented into monoclonal antibodies, granulocyte colony-stimulating factor, and erythropoiesis-stimulating agents. In 2023, the monoclonal antibodies segment held the largest share of the market and is anticipated to register the highest CAGR from 2023 to 2031. The market, based on cancer type, is categorized into lung cancer, colorectal cancer, cervical cancer, breast cancer, stomach cancer, brain cancer, and others. The lung cancer segment held the largest oncology biosimilars market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. The oncology biosimilars market is segmented based on distribution channels into hospital pharmacies, retail pharmacies, and online pharmacies. In 2023, the hospital pharmacy segment held the largest market share and is expected to register the highest CAGR from 2023 to 2031.

Oncology biosimilars: Geographical Overview

The scope of the global oncology biosimilars report entails North America (the US,

Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America held a major oncology biosimilars share in 2023, followed by Europe; the market in Asia Pacific region is growing with the highest CAGR during the forecast period. This is attributed to developing healthcare infrastructure in emerging markets, rising healthcare expenditure, lucrative reimbursement policies, and increasing emphasis on better patient outcomes in the region.

Contents

1. INTRODUCTION

- 1.1 Scope of the Study
- 1.2 Market Definition, Assumptions and Limitations
- 1.3 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness Analysis

3. RESEARCH METHODOLOGY

4. ONCOLOGY BIOSIMILARS MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis
- 4.3 Ecosystem Analysis
 - 4.3.1 List of Vendors in the Value Chain

5. ONCOLOGY BIOSIMILARS MARKET - KEY MARKET DYNAMICS

- 5.1 Key Market Drivers
- 5.2 Key Market Restraints
- 5.3 Key Market Opportunities
- 5.4 Future Trends
- 5.5 Impact Analysis of Drivers and Restraints

6. ONCOLOGY BIOSIMILARS MARKET - GLOBAL MARKET ANALYSIS

- 6.1 Oncology Biosimilars - Global Market Overview
- 6.2 Oncology Biosimilars - Global Market and Forecast to 2031

7. ONCOLOGY BIOSIMILARS MARKET – REVENUE ANALYSIS (USD MILLION) – BY DRUG CLASS, 2021-2031

- 7.1 Overview

- 7.2 Monoclonal Antibodies
- 7.3 Erythropoiesis-Stimulating Agents
- 7.4 Granulocyte Colony-Stimulating Factor (G-CSF)

8. ONCOLOGY BIOSIMILARS MARKET – REVENUE ANALYSIS (USD MILLION) – BY CANCER TYPE, 2021-2031

- 8.1 Overview
- 8.2 Colorectal Cancer
- 8.3 Cervical Cancer
- 8.4 Breast Cancer
- 8.5 Supportive Care
- 8.6 Lymphoma
- 8.7 Others

9. ONCOLOGY BIOSIMILARS MARKET – REVENUE ANALYSIS (USD MILLION) – BY DISTRIBUTION CHANNEL , 2021-2031

- 9.1 Overview
- 9.2 Hospital Pharmacy
- 9.3 Retail Pharmacy
- 9.4 Online Pharmacy

10. ONCOLOGY BIOSIMILARS MARKET - REVENUE ANALYSIS (USD MILLION), 2021-2031 – GEOGRAPHICAL ANALYSIS

- 10.1 North America
 - 10.1.1 North America Oncology Biosimilars Market Overview
 - 10.1.2 North America Oncology Biosimilars Market Revenue and Forecasts to 2031
 - 10.1.3 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Drug Class
 - 10.1.4 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Cancer Type
 - 10.1.5 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Distribution Channel
 - 10.1.6 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Countries
 - 10.1.6.1 United States Oncology Biosimilars Market
 - 10.1.6.1.1 United States Oncology Biosimilars Market, by Drug Class

- 10.1.6.1.2 United States Oncology Biosimilars Market, by Cancer Type
- 10.1.6.1.3 United States Oncology Biosimilars Market, by Distribution Channel
- 10.1.6.2 Canada Oncology Biosimilars Market
 - 10.1.6.2.1 Canada Oncology Biosimilars Market, by Drug Class
 - 10.1.6.2.2 Canada Oncology Biosimilars Market, by Cancer Type
 - 10.1.6.2.3 Canada Oncology Biosimilars Market, by Distribution Channel
- 10.1.6.3 Mexico Oncology Biosimilars Market
 - 10.1.6.3.1 Mexico Oncology Biosimilars Market, by Drug Class
 - 10.1.6.3.2 Mexico Oncology Biosimilars Market, by Cancer Type
 - 10.1.6.3.3 Mexico Oncology Biosimilars Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe

- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe

10.3 Asia-Pacific

- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific

10.4 Middle East and Africa

- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa

10.5 South and Central America

- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. INDUSTRY LANDSCAPE

11.1 Mergers and Acquisitions

11.2 Agreements, Collaborations, Joint Ventures

11.3 New Product Launches

11.4 Expansions and Other Strategic Developments

12. COMPETITIVE LANDSCAPE

12.1 Heat Map Analysis by Key Players

12.2 Company Positioning and Concentration

13. ONCOLOGY BIOSIMILARS MARKET - KEY COMPANY PROFILES

13.1 Biocon

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

13.2 Celltrion Inc

13.3 Samsung Bioepis

13.4 Amgen Inc

13.5 Coherus BioSciences

13.6 Pfizer Inc

13.7 Sandoz International GmbH (A Novartis Division)

13.8 Teva Pharmaceutical Industries Ltd.

13.9 Lilly

13.10 BIOCAD

14. APPENDIX

14.1 Glossary

14.2 About The Insight Partners

14.3 Market Intelligence Cloud

I would like to order

Product name: Oncology Biosimilars Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, and Erythropoiesis-Stimulating Agents), Cancer Type (Colorectal Cancer, Cervical Cancer, Breast Cancer, Supportive Care, Lymphoma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Product link: <https://marketpublishers.com/r/O02A23A33F1FEN.html>

Price: US\$ 5,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O02A23A33F1FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970